AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

In8Bio Announces Pricing Of Financing Totaling Up To $46.9 Million In Private Placement

Dec 11, 2023•over 1 year ago

New YorkBiotechnology Research

Description

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors to raise up to $46.9 million at increasing valuations that includes initial gross proceeds of $14.4 million, extending the Company’s runway into 2025.

Company Information

Company

IN8bio

Location

New York, New York, United States

About

IN8bio Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cell based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic.

Company News

(10 articles)

Thu, 07 Aug 2025 07:00:00 GMT

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance

Tue, 29 Apr 2025 07:00:00 GMT

IN8bio Unveils New Clinical Data for Revolutionary Gamma-Delta T Cell Cancer Treatment at ASCO, AACR - Stock Titan

Mon, 28 Apr 2025 07:00:00 GMT

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 - Yahoo Finance

Tue, 18 Mar 2025 07:00:00 GMT

IN8bio Unveils Groundbreaking Gamma-Delta T Cell Program at Major IO Conference - Stock Titan

Tue, 29 Apr 2025 07:00:00 GMT

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences - Yahoo Finance

Wed, 14 Aug 2024 07:00:00 GMT

IN8bio Secures FDA Guidance on Bringing Gamma-Delta T-cell Therapy INB-100 to Pivotal AML Trial - CGTLive®

Thu, 05 Sep 2024 07:00:00 GMT

IN8bio to Lay Off About 49% of Employees - BioSpace

Tue, 11 Feb 2025 08:00:00 GMT

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients - The Manila Times